Neogenomics (NEO) Stock Price
Neogenomics Price
Over the last 19 years Neogenomics grew revenue by 28.2% annually, reaching 727.33 M USD. Earnings per share have grown at 50.4% per year over the last 8 years. For Neogenomics, the net margin of -14.9% is down versus -1.7% a few years ago. The consensus 12-month price target for Neogenomics is 14.28 USD, about 17.8% below where the stock trades today. Of 17 analysts, 8 rate the stock a buy — an overall Hold consensus. The stock trades about 142% above its 52-week low.
Neogenomics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Neogenomics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Neogenomics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Neogenomics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Neogenomics Price |
|---|---|
| 9/4/2026 | 17.38 USD |
| 9/3/2026 | 17.46 USD |
| 9/2/2026 | 17.40 USD |
| 9/1/2026 | 17.45 USD |
| 8/31/2026 | 17.91 USD |
| 8/30/2026 | 17.65 USD |
| 8/28/2026 | 18.00 USD |
| 8/27/2026 | 18.95 USD |
| 8/26/2026 | 17.37 USD |
| 8/25/2026 | 16.79 USD |
| 8/24/2026 | 16.59 USD |
| 8/21/2026 | 16.98 USD |
| 8/20/2026 | 16.53 USD |
| 8/19/2026 | 16.34 USD |
| 8/18/2026 | 15.90 USD |
| 8/14/2026 | 15.94 USD |
| 8/13/2026 | 16.39 USD |
| 8/12/2026 | 16.42 USD |
| 8/11/2026 | 16.53 USD |
| 8/10/2026 | 16.60 USD |
| 8/7/2026 | 16.57 USD |
| 8/6/2026 | 15.56 USD |
| 8/5/2026 | 15.99 USD |
| 8/4/2026 | 16.15 USD |
| 8/3/2026 | 15.84 USD |
| 7/31/2026 | 15.29 USD |
| 7/30/2026 | 15.88 USD |
| 7/29/2026 | 15.83 USD |
| 7/27/2026 | 13.49 USD |
| 7/23/2026 | 14.24 USD |
Neogenomics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Neogenomics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.10 | 0.24 | 0.24 | 0.28 | 0.41 | 0.44 | 0.48 | 0.51 | 0.59 | 0.66 | 0.73 | 0.80 | 0.88 | 0.97 | 1.03 | 1.11 |
| 13.79 | 146.46 | -1.64 | 15.00 | 47.83 | 8.82 | 9.01 | 5.17 | 16.11 | 11.68 | 10.15 | 10.59 | 9.95 | 9.16 | 6.63 | 7.97 |
| 43.43 | 45.08 | 42.08 | 46.01 | 48.04 | 41.67 | 38.64 | 36.74 | 41.29 | 43.94 | 38.79 | 38.79 | 38.79 | 38.79 | 38.79 | 38.79 |
| 43.00 | 110.00 | 101.00 | 127.00 | 196.00 | 185.00 | 187.00 | 187.00 | 244.00 | 290.00 | 282.00 | 311.87 | 342.90 | 374.32 | 399.14 | 430.95 |
| -5.00 | 2.00 | 2.00 | 10.00 | 7.00 | -7.00 | -9.00 | -157.00 | -107.00 | -92.00 | -66.00 | 11.00 | 15.00 | 21.00 | 26.00 | 29.00 |
| -5.05 | 0.82 | 0.83 | 3.62 | 1.72 | -1.58 | -1.86 | -30.84 | -18.10 | -13.94 | -9.08 | 1.37 | 1.70 | 2.18 | 2.53 | 2.61 |
| -2.00 | -6.00 | – | 2.00 | 8.00 | 4.00 | -8.00 | -144.00 | -87.00 | -78.00 | -108.00 | 23.00 | 42.00 | 59.00 | 87.00 | 102.00 |
| -300.00 | 200.00 | – | – | 300.00 | -50.00 | -300.00 | 1,700.00 | -39.58 | -10.34 | 38.46 | -121.30 | 82.61 | 40.48 | 47.46 | 17.24 |
| 12.17 | 78.49 | 15.89 | 19.37 | 21.56 | 22.85 | 24.62 | 24.94 | 25.19 | 25.33 | 25.73 | 25.73 | 25.73 | 25.73 | 25.73 | 25.73 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Neogenomics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Neogenomics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Neogenomics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Neogenomics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Neogenomics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Neogenomics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Neogenomics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Neogenomics business model & stock analysis
Neogenomics SWOT Analysis
Strengths
Neogenomics Inc holds a prominent position in the molecular testing and genetic analysis market. Its advanced technologies and expertise in oncology diagnostics give it a competitive advantage.
The company offers a wide range of testing services, including genetic testing, cytogenetics, flow cytometry, and pathology consultations. This diverse portfolio allows Neogenomics to cater to various customer needs.
Neogenomics has established collaborations with pharmaceutical companies, research institutions, and healthcare providers. These partnerships enhance its research capabilities and provide access to a larger customer base.
Weaknesses
The company operates in a highly regulated industry where changes in compliance requirements can impact its operations. Ensuring adherence to evolving regulations can be a potential weakness.
Neogenomics relies on reimbursement from insurance providers and government programs for its testing services. Any changes in reimbursement policies may affect the company's financial performance.
Maintaining advanced testing technologies and the need for highly skilled professionals contribute to Neogenomics' higher operating costs compared to some competitors.
Opportunities
The growing focus on personalized medicine creates opportunities for Neogenomics to expand its genetic testing services. Precision medicine can enhance treatment outcomes and drive demand for the company's advanced diagnostics.
The emergence of liquid biopsy as a non-invasive method for cancer detection presents an opportunity for Neogenomics. Investing in this technology can help the company capture a significant share of the liquid biopsy market.
Neogenomics can explore new markets beyond the United States to broaden its customer base. International expansion can provide access to untapped revenue streams and diversify its geographical risk.
Threats
The molecular testing and genetic analysis market is highly competitive, with several established players. Neogenomics faces the risk of losing market share to competitors that offer similar or more innovative services.
Rapid advancements in technology can quickly make existing diagnostic techniques obsolete. Neogenomics needs to stay at the forefront of technological developments to remain competitive and meet evolving customer expectations.
During periods of economic recession or downturns in healthcare spending, Neogenomics may experience a decline in demand for its high-cost testing services. The company needs to be prepared for potential fluctuations in market demand.
Neogenomics Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Neogenomics Segments
Neogenomics Revenue by Segment (1/2)
3 Years
5 Years
Max
Details
Neogenomics Revenue by Segment (2/2)
3 Years
5 Years
Max
Details
Neogenomics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Neogenomics historical P/E ratio, EBIT multiple, and P/S ratio
Neogenomics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Neogenomics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Neogenomics stock splits
Current Neogenomics forecasts and price targets in September 2026
Analyst Price Targets 2026Neogenomics Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 7/29/2026 | Maintained | Buy | 70 | |
| 7/24/2026 | Maintained | Buy | 72 | |
| 4/29/2026 | Maintained | Buy | 60 | |
| 4/29/2026 | Upgrade | Market PerformOutperform | – | |
| 4/29/2026 | Upgrade | HoldBuy | 72 | |
| 2/24/2026 | Maintained | Overweight | 50 | |
| 2/17/2026 | Maintained | Buy | 70 | |
| 1/12/2026 | Maintained | Buy | 70 | |
| 9/12/2025 | Maintained | Buy | 60 | |
| 9/2/2025 | Maintained | Overweight | 67 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Neogenomics Earnings Calls
Neogenomics Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 7/28/2026 | 0.03USD | - | 198.97 MUSD | - | 2026 Q2 |
| 4/28/2026 | 0.01USD | - | 186.38 MUSD | - | 2026 Q1 |
| 2/17/2026 | 0.04USD | - | 189.93 MUSD | - | 2025 Q4 |
| 5/6/2024 | -0.05USD | - | 151.96 MUSD | - | 2024 Q1 |
| 2/21/2024 | -0.03USD | - | 154.06 MUSD | - | 2023 Q4 |
| 11/6/2023 | -0.13USD | - | 138.66 MUSD | - | 2023 Q3 |
| 8/7/2023 | -0.13USD | - | 135.86 MUSD | - | 2023 Q2 |
| 4/25/2023 | -0.16USD | - | 128.48 MUSD | - | 2023 Q1 |
| 2/21/2023 | -0.18USD | - | 131.08 MUSD | - | 2022 Q4 |
| 11/8/2022 | -0.21USD | - | 123.36 MUSD | - | 2022 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Neogenomics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Neogenomics shareholder structure
| % | Name |
|---|---|
15.75700% | |
7.68209% | |
7.18478% | |
6.01793% | |
4.86536% | |
4.46543% |
Neogenomics Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
15.70% | SEC ↗ | |
14.60% | SEC ↗ | |
10.71% | SEC ↗ | |
10.47% | SEC ↗ | |
10.04% | SEC ↗ | |
9.50% | SEC ↗ | |
9.50% | SEC ↗ | |
9.50% | SEC ↗ | |
9.29% | SEC ↗ | |
9.24% | SEC ↗ |
Neogenomics Executives and Management Board
13 members · avg. age 60 · 38 % women
Mr. Jeffrey Sherman (59)
Chief Financial Officer
3.48 M USD
Management
Mr. Warren Stone (52)
President, Chief Operating Officer
Ms. Alicia Olivo (41)
Executive Vice President, General Counsel & Business Development
Mr. Antony Zook (64)
Chief Executive Officer, Director · since 2023
Mr. Gregory Aunan (55)
Chief Accounting Officer
Board of Directors
Ms. Lynn Tetrault (62)
Independent Chairman of the Board · since 2015
Mr. Michael Kelly (68)
Lead Independent Director
Dr. Neil Gunn (64)
Independent Director
Mr. Stephen Kanovsky (62)
Independent Director
Mr. David Perez (65)
Independent Director
Dr. Alison Hannah (64)
Independent Director
Neogenomics Supply Chain
Neogenomics Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.78 | — | — | ||
| 2 | -0.90 | -0.68 | — | ||
| 3 | 0.79 | 0.02 | -0.32 | ||
| 4 | 0.74 | 0.58 | 0.04 |
Frequently asked questions about Neogenomics
Neogenomics Inc. (NYSE: NEO) is a leading provider of cancer-focused genetic testing services. The company's business model revolves around offering comprehensive testing solutions that aid in the diagnosis and treatment of cancer patients. Neogenomics Inc. operates through a network of laboratories and provides advanced molecular and cytogenetic testing, helping healthcare professionals make informed decisions based on genetic information. With a focus on precision medicine, Neogenomics Inc. delivers personalized treatment options, improving patient outcomes and delivering high-quality diagnostic services.
Neogenomics Inc is primarily active in the healthcare and diagnostic laboratory services industries.
The main competitors of Neogenomics Inc in the market are Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, and NeoGenomics Laboratories.
Neogenomics Inc is a leading provider of cancer-focused genetic testing services. Founded in 2001, the company is headquartered in Fort Myers, Florida. With an extensive network of laboratories across the United States, Neogenomics offers cutting-edge diagnostic and pharmaceutical services to aid in the personalized treatment and monitoring of various types of cancers. Over the years, Neogenomics has grown its portfolio of tests and services, catering to the evolving needs of healthcare professionals and patients. Their dedication to innovation and quality has positioned them as a trusted partner in the fight against cancer.
Some significant milestones achieved by Neogenomics Inc include its acquisition of Clarient Inc in 2015, which expanded its personalized medicine capabilities. The company also received full approval from the New York State Department of Health in 2017, allowing it to offer its services in all 50 states. Neogenomics Inc has strengthened its position in the molecular testing market through strategic collaborations with pharmaceutical companies. Furthermore, in 2019, the company completed its acquisition of Genoptix, enhancing its oncology diagnostics capabilities. These milestones demonstrate Neogenomics Inc's commitment to growth and innovation in the field of cancer diagnostics and personalized medicine.
Neogenomics Inc is primarily present in the United States.
Neogenomics Inc prides itself on its commitment to excellence and innovation in the field of precision medicine. With a strong corporate philosophy centered around patient care and advancing the fight against cancer, Neogenomics Inc places great importance on ethical practices and providing accurate diagnostic solutions. The company believes in fostering a collaborative environment to bring cutting-edge technologies and personalized medicine to patients globally. By constantly pushing boundaries and embracing transformative ideas, Neogenomics Inc aims to revolutionize how cancer is detected and treated. Through its dedication to quality, integrity, and patient-centric values, the company sets itself apart as a leader in the field.
Analysts currently set an average price target of 13.77 USD for the Neogenomics stock (median: 14.28 USD), implying -20.8 % versus the latest price. The consensus is based on 17 analyst ratings.
17 analysts currently rate the Neogenomics stock: 8 recommend buying, 8 holding and 1 selling. For 2026, analysts expect Neogenomics to generate revenue of 804.16 M USD and earnings per share of 0.90 USD.
Converted at the current exchange rate, the Neogenomics share trades at 14.95 EUR (17.38 USD).
The Neogenomics share (NEO) is listed on 5 stock exchanges, including: NASDAQ (NEO), Frankfurt (NG9.F), München (NG9.MU), Düsseldorf (NG9.DU), SIX (Zürich) (NG9.SW).
Neogenomics Inc is a leading company in oncology diagnostics and offers a wide range of solutions and products to its customers. The company has been listed on the stock exchange since 2001 and is the largest provider of cancer diagnostics services in the United States. Translate the text to the best possible English.
The expected revenue of Neogenomics is 804.16 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Neogenomics is 23.14 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Neogenomics is currently 19.32. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Neogenomics stock.
The price-to-sales ratio (P/S) of Neogenomics is currently 0.56. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Neogenomics stock.
The Eulerpool Quality Score for Neogenomics is 3/10.
The ISIN of Neogenomics is US64049M2098. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Neogenomics is 120159. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Neogenomics is NEO. The ticker symbol is used to trade Neogenomics shares on the stock exchange.
Neogenomics paid dividends every year for the past 0 years.
Neogenomics is assigned to the 'Health' sector.
The dividends of Neogenomics are distributed in USD.
Neogenomics stock
Neogenomics Peer Group
Neogenomics Ticker
Neogenomics FIGI
All fundamentals and in-depth analysis of Neogenomics
Our stock analysis for Neogenomics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neogenomics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.